Tarsus Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $66,408 | $48,118 | $40,813 | $27,614 |
Gross Profit | 61,482 | 44,876 | 37,809 | 25,960 |
EBITDA | -20,507 | -20,675 | -30,942 | -34,478 |
EBIT | -20,939 | -20,959 | -31,181 | -34,748 |
Net Income | -23,113 | -23,420 | -33,290 | -35,731 |
Net Change In Cash | 66,408 | 48,118 | 40,813 | 27,614 |
Free Cash Flow | -27,254 | -8,934 | -15,443 | -37,963 |
Cash | 94,819 | 176,210 | 181,095 | 193,705 |
Basic Shares | 37,604 | 38,381 | 37,823 | 35,300 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $182,953 | $17,447 | $25,816 | $57,027 |
Gross Profit | 170,127 | 15,854 | 24,861 | 54,952 |
EBITDA | -106,882 | -131,670 | -59,107 | -13,166 |
EBIT | -108,107 | -132,547 | -59,896 | -13,772 |
Net Income | -115,554 | -135,893 | -62,091 | -13,827 |
Net Change In Cash | 182,953 | 17,447 | 25,816 | 57,027 |
Cost of Revenue | -99,672 | 3,183 | ||
Free Cash Flow | -84,594 | -122,995 | -49,536 | 3,162 |
Cash | 94,819 | 224,947 | 71,660 | 171,332 |
Basic Shares | 37,604 | 29,383 | 24,619 | 20,554 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.60 |
2024-09-30 | -$0.61 |
2024-06-30 | -$0.88 |
2024-03-31 | -$1.01 |
